Signals, Powered By EquityPandit
Lupin has received final approval to market its Tetrabenazine tablets, from the US health regulator. It is used for treating involuntary movements associated with Huntington’s disease.
It has received approval to market the 12.5 mg and 25 mg tablets from the United States Food and Drug Administration (USFDA). The tablets are generic versions of Valeant Pharmaceuticals North America LLC’s Xenazine tablets in the same strengths. Furthermore, it is suggested for the treatment of chorea associated with Huntington’s disease.
